Jefferies Downgrades Reata Pharmaceuticals to Hold, Raises Price Target to $172.5
Portfolio Pulse from richadhand@benzinga.com
Jefferies analyst Maury Raycroft has downgraded Reata Pharmaceuticals from Buy to Hold, while raising the price target from $104 to $172.5.
July 31, 2023 | 9:25 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Reata Pharmaceuticals has been downgraded from Buy to Hold by Jefferies, but the price target has been raised from $104 to $172.5.
The downgrade from Buy to Hold suggests that Jefferies sees limited upside potential for Reata Pharmaceuticals in the short term. However, the raised price target indicates that they still see long-term value in the stock. This could lead to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100